Alaunos Therapeutics, Inc. (NASDAQ:TCRT – Get Free Report) was down 0.5% on Monday . The company traded as low as $1.88 and last traded at $1.95. Approximately 9,989 shares traded hands during mid-day trading, a decline of 44% from the average daily volume of 17,924 shares. The stock had previously closed at $1.96.
Alaunos Therapeutics Price Performance
The firm has a 50 day moving average of $2.19 and a 200-day moving average of $3.52.
About Alaunos Therapeutics
Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers.
Read More
- Five stocks we like better than Alaunos Therapeutics
- What is a Special Dividend?
- Top 3 Reasons to Invest in This Bond ETF for Stability and Growth
- Market Cap Calculator: How to Calculate Market Cap
- 2 Drone Stocks Surging from Increased Media Attention
- 3 Stocks to Consider Buying in October
- Ciena Rebounds: AI and Strong Guidance Drive Post-Earnings Surge
Receive News & Ratings for Alaunos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alaunos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
